CHRD

CHRD (chordin) is a secreted BMP antagonist that establishes tissue polarity during embryonic development by sequestering BMP ligands in latent extracellular complexes, thereby restricting BMP receptor activation across dorsoventral, left-right, and limb axes. CHRD binds BMP2, BMP4, and BMP7, and this antagonism is potentiated by TWSG1; BMP1 metalloprotease cleaves CHRD to release bound BMPs and restore signaling (PMID:9782094, PMID:37338142, PMID:34517078). Genetic loss of Chrd, alone or with Nog, disrupts gastrula organizer function, neural crest development, cephalic vascular patterning, and left-right axis establishment by derepressing BMP signaling in the lateral plate mesoderm, where CHRD is required for Nodal transcription (PMID:12397106, PMID:16894609, PMID:17685487, PMID:18550712). Transcription of chrd is directly activated by Smad2/3 at activin response elements and by Goosecoid at GRE sites in the promoter, and repressed by Foxd4l1.1 and Ventx1.1, integrating TGF-β/activin, Wnt, and ventral homeobox inputs into a tightly regulated BMP-antagonist output (PMID:33945994, PMID:34685759, PMID:36980215).

1. 1998 High

   Establishing that mammalian chordin is a secreted dorsalizing factor that binds BMPs answered the fundamental question of whether the Xenopus/Drosophila-discovered BMP antagonist mechanism is conserved in mammals.

   Evidence cDNA cloning, RNA blot analysis, and radiation hybrid mapping of mouse Chrd

   PMID:9782094

   Open questions at the time

   • Binding affinities for individual BMP ligands not quantified
   • No loss-of-function data in mammals yet
2. 2001 High

   Demonstrating that alternatively spliced C-truncated CHRD variants retain BMP-antagonist activity revealed that post-transcriptional processing, not just BMP1-mediated cleavage, generates biologically active sub-products.

   Evidence cDNA cloning of human splice variants and Xenopus axis-duplication functional assay

   PMID:11472837

   Open questions at the time

   • Relative abundance of splice variants in vivo unknown
   • Whether splice variants have distinct BMP-binding specificities untested
3. 2002 High

   Compound Chrd/Nog mutant analysis established that CHRD and Noggin act redundantly in the mouse organizer to limit BMP signaling, which is required for SHH and FGF8 expression at rostral organizing centers — answering how BMP antagonism links to downstream patterning genes.

   Evidence Chrd/Nog compound mutant mouse embryos with in situ hybridization and ectopic BMP2 application

   PMID:12397106

   Open questions at the time

   • Individual contributions of CHRD versus Noggin to each organizer function not fully resolved
   • Downstream transcriptional targets beyond SHH and FGF8 uncharacterized
4. 2006 High

   Loss-of-function studies extended CHRD's developmental role beyond axial patterning to neural crest generation, emigration, and survival, and to cephalic vascular morphogenesis, showing that BMP antagonism by CHRD is required in multiple tissue contexts.

   Evidence Chrd single and Chrd/Nog compound mutant mice with immunostaining, apoptosis assays, and vascular casting

   PMID:16894609 PMID:17685487

   Open questions at the time

   • Cell-autonomous versus non-autonomous requirement for CHRD in neural crest not distinguished
   • Molecular basis of vascular patterning defect beyond elevated BMP signaling unclear
5. 2008 High

   Demonstrating that CHRD limits BMP signaling in the left lateral plate mesoderm to permit Nodal expression resolved how BMP antagonism feeds into left-right axis determination.

   Evidence Chrd/Nog double-mutant mice with in situ hybridization and electroporation rescue of Nog in left LPM

   PMID:18550712

   Open questions at the time

   • Whether CHRD acts by direct BMP4/7 sequestration versus indirect signaling in LPM not resolved
   • How CHRD asymmetry in LPM is initially established is unknown
6. 2017 High

   Placing CHRD as a downstream effector of Shh that antagonizes BMP signaling during interdigital cell death established a Shh→Chrd→BMP inhibition axis in limb morphogenesis.

   Evidence Transcriptome analysis of Hm mutant limbs and phenotypic recapitulation in Chrd-overexpressing transgenic mice

   PMID:29255029

   Open questions at the time

   • Whether CHRD is the sole mediator of Shh-dependent BMP antagonism in limb unclear
   • Direct Shh-responsive cis-elements in Chrd promoter not identified
7. 2021 High

   Identification of Smad2/3 binding to discrete activin response elements (ARE1, ARE2) in the chrd promoter answered how TGF-β/activin signaling directly activates CHRD transcription, with Smad2 and Smad3 showing differential element usage.

   Evidence ChIP, reporter assays, and site-directed mutagenesis of chrd promoter in Xenopus gastrula embryos

   PMID:33945994

   Open questions at the time

   • Whether mammalian CHRD promoter has equivalent AREs not confirmed
   • Cofactors recruited by Smad2/3 to the chrd promoter unidentified
8. 2021 High

   Foxd4l1.1 was shown to repress chrd both by direct promoter binding and by sequestering Smad2/3 away from AREs, revealing a dual-mechanism transcriptional repressor that links neuroectodermal specification to CHRD downregulation.

   Evidence ChIP-PCR, co-immunoprecipitation, reporter assays, and FRE mutagenesis in Xenopus embryos

   PMID:34685759

   Open questions at the time

   • Whether Foxd4l1.1 homologs in mammals repress CHRD similarly untested
   • Stoichiometric relationship between Foxd4l1.1 and Smad2/3 not quantified
9. 2021 Medium

   TWSG1 was shown to synergistically enhance CHRD antagonism of BMP2, BMP4, BMP7, and GDF5, expanding the functional BMP-binding repertoire of the CHRD system beyond its solo activity.

   Evidence BMP bioactivity assays with recombinant proteins and expression profiling in ovarian tissues

   PMID:34517078

   Open questions at the time

   • Direct physical complex between TWSG1 and CHRD not confirmed
   • Physiological relevance of CHRD-TWSG1 synergy in non-ovarian tissues untested
10. 2023 High

    Mapping of Goosecoid (GRE) and Ventx1.1 (VRE) response elements in the chrd promoter completed a cis-regulatory logic integrating organizer-specific activation and ventral repression of CHRD transcription.

    Evidence ChIP-PCR, reporter assays, and site-directed mutagenesis in Xenopus gastrula embryos

    PMID:36980215

    Open questions at the time

    • Whether GRE and VRE are conserved in the mammalian CHRD promoter is unknown
    • How TCF7/Wnt signaling at the adjacent WRE integrates with Gsc activation not fully resolved
11. 2023 Medium

    O-fucosylation of BMP1 by poFUT1 was shown to enhance BMP1 secretion and its binding to CHRD, releasing CHRD-bound BMP4 to activate Smad signaling in endometrial decidualization — extending the BMP1-CHRD axis to a new physiological context.

    Evidence Co-immunoprecipitation, ELISA, overexpression/knockdown in human endometrial stromal cells

    PMID:37338142

    Open questions at the time

    • BMP1-CHRD binding stoichiometry and cleavage site usage in this context not defined
    • Whether other tolloid-family proteases substitute for BMP1 in the endometrium untested

• A structural model of the full-length CHRD-BMP complex, quantitative binding affinities for individual BMP ligands, and the in vivo relevance of individual CHRD splice variants remain unresolved.
• No crystal or cryo-EM structure of full-length CHRD bound to BMPs
• Relative contributions of individual cysteine-rich domains to BMP specificity not mapped
• Functional significance of each CHRD splice variant in mammalian tissues undefined